The third quarter's "pre happiness" can hardly hide the embarrassment of drug companies' growth

Source: e-medicine Facebook on October 14, 2015, according to statistics, of the 71 pharmaceutical companies that published the third quarter report, 58 achieved a year-on-year increase in net profit Among the seven enterprises whose net profit has doubled, Shanghai Laishi, Yifan Xinfu and Erkang pharmaceutical have made a large increase in net profit in the third quarter of this year due to their large net profit base in the same period of last year, with the highest net profit reaching 1.181 billion yuan, 323 million yuan and 459 million yuan respectively The net profit base of other companies in the previous year is relatively small, so although the increase is high, the final net profit scale is still small Taking wohua pharmaceutical as an example, as the first company to appear in the third quarter report of the two cities, although its net profit increased 252.1% year on year, its actual value was only 61.3898 million yuan In addition, the net profit of 29 enterprises remained between 20% and 100% Overall, although the net profit of pharmaceutical companies shows a growth trend, the growth rate is still slow Industry insiders said that the increase of medical insurance cost restrictions and the downward trend of the general environment will lead to a relatively slow growth trend of the pharmaceutical manufacturing industry for a long time in the future In recent years, thanks to the rapid expansion of medical insurance coverage and the substantial increase of government financial investment, the income of pharmaceutical manufacturing industry has achieved a rapid growth, once reaching about 30% Since 2011, the growth rate has slowed down to 10% - 20%, and this year's growth rate has returned to 9% 2015 is a big year for bidding Pharmaceutical enterprises are still facing high risk of price reduction, and the growth rate of the industry continues to slow down It is understood that in the first half of this year, the growth rate of pharmaceutical manufacturing revenue reached a new low of 15 years, with a growth rate of only 8.76% Before that, the growth rate of industrial income fell below 10% only before 2000, when it was due to the lack of medical insurance system for urban employees However, in 2003, 2007, the new rural cooperative medical system (NCMS) and the urban residents' medical insurance have been established respectively At the moment when the aging demand is constantly released, it is extremely rare that the growth rate falls below double digits According to the data from the South Office of the State Food and drug administration, the growth rate of sales revenue of the pharmaceutical industry reached 26% in 2011, and then declined year by year, 17.9% in 2013 and 12.5% in 2014 Industry insiders believe that the rapid growth of hospital and retail terminal sales channels is the main reason for the slowdown in the growth of industry revenue In terms of profit, after the profit growth rate of 32.7% in 2010, the profit of pharmaceutical industry declined all the way In 2013, the profit growth rate was 17.6%, and in 2014, it was only 12% The decline of profit growth is mainly restricted by medical insurance control fees, low-cost bidding and GMP transformation costs Some insiders in the pharmaceutical industry said that the profit growth rate of pharmaceutical manufacturing enterprises continued to decline this year, mainly because of the changes in the rules of drug sales With the implementation of the medical insurance payment price and the implementation of the second bargaining policy, the drug price will be further depressed At the same time, the income growth of the national health insurance system is limited and the expenditure increases rapidly, which also leads to the obvious slowdown of the sales growth of the best-selling drugs and the difficulty of new drugs listing It is worth noting that the "touch the net" of prescription drugs will also change the traditional hospital centered sales channels, which will pose continuous pressure on the pharmaceutical industry.